GSK3B and myotonic dystrophy type 1: Although more pre-clinical work is needed to determine whether the inhibitors of GSK3 reduce brain atrophy in homozygous DMSXL mice, this study shows that the correction of CUGBP1 activity via GSK3β signaling is a critical target in DM1 therapy.